JAK Signaling Is Critically Important in Cytokine-Induced Viral Susceptibility of Keratinocytes

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jun 10

PMID 37298195

Authors

Kimberly A Arnold

Liam F Peterson

Lisa A Beck

Matthew G Brewer

Affiliations

Soon will be listed here.

Abstract

Little is known about whether type 1 (IFNγ), 2 (IL-4/IL-13), or 3 (IL-17A/IL-22) cytokines affect the susceptibility of keratinocytes (KC) to viruses. These immune pathways predominate in various skin diseases: lupus, atopic dermatitis (AD), and psoriasis, respectively. Janus kinase inhibitors (JAKi) are approved to treat both AD and psoriasis, and are in clinical development for lupus. We evaluated whether these cytokines alter viral susceptibility of KC and determined if this effect is modulated by treatment with JAKi. Viral susceptibility to vaccinia virus (VV) or herpes simplex virus-1 (HSV-1) ± JAKi was assessed in immortalized and primary human KC pretreated with cytokines. Exposure to type 2 (IL-4 + IL-13) or the type 3 (IL-22) cytokines significantly increased KC viral susceptibility. Specifically, there was a peak increase of 12.2 ± 3.1-fold (IL-4 + IL-13) or 7.7 ± 2.8-fold (IL-22) in VV infection as measured by plaque number. Conversely, IFNγ significantly reduced susceptibility to VV (63.1 ± 64.4-fold). The IL-4 + IL-13-induced viral susceptibility was reduced (44 ± 16%) by JAK1 inhibition, while the IL-22-enhanced viral susceptibility was diminished (76 ± 19%) by TYK2 inhibition. IFNγ-mediated resistance to viral infection was reversed by JAK2 inhibition (366 ± 294% increase in infection). Cytokines expressed in AD skin (IL-4, IL-13, IL-22) increase KC viral susceptibility while IFNγ is protective. JAKi that target JAK1 or TYK2 reversed cytokine-enhanced viral susceptibility, while JAK2 inhibition reduced the protective effects of IFNγ.

Citing Articles

Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma.

Ashton L, Weishaar K, Seguin B, MacNeill A Biomedicines. 2023; 11(9).

PMID: 37760788 PMC: 10525839. DOI: 10.3390/biomedicines11092346.

References

Qing Y, Stark G . Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004; 279(40):41679-85. DOI: 10.1074/jbc.M406413200. View

Rhein B, Powers L, Rogers K, Anantpadma M, Singh B, Sakurai Y . Interferon-γ Inhibits Ebola Virus Infection. PLoS Pathog. 2015; 11(11):e1005263. PMC: 4643030. DOI: 10.1371/journal.ppat.1005263. View

Vora S, Damon I, Fulginiti V, Weber S, Kahana M, Stein S . Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis. 2008; 46(10):1555-61. DOI: 10.1086/587668. View

Brewer M, Monticelli S, Moran M, Miller B, Beck L, Ward B . Conditions That Simulate the Environment of Atopic Dermatitis Enhance Susceptibility of Human Keratinocytes to Vaccinia Virus. Cells. 2022; 11(8). PMC: 9025056. DOI: 10.3390/cells11081337. View

Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T . Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020; 82(4):823-831. DOI: 10.1016/j.jaad.2019.12.015. View

Silverberg J, Simpson E, Thyssen J, Gooderham M, Chan G, Feeney C . Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020; 156(8):863-873. PMC: 7271424. DOI: 10.1001/jamadermatol.2020.1406. View

Blauvelt A, Silverberg J, Lynde C, Bieber T, Eisman S, Zdybski J . Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2021; 86(1):104-112. DOI: 10.1016/j.jaad.2021.05.075. View

Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, Karoui K, Roy L . Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022; 12(1):7140. PMC: 9065106. DOI: 10.1038/s41598-022-10777-w. View

Moran M, Pandya R, Leffler K, Yoshida T, Beck L, Brewer M . Characterization of Human Keratinocyte Cell Lines for Barrier Studies. JID Innov. 2021; 1(2):100018. PMC: 8659750. DOI: 10.1016/j.xjidi.2021.100018. View

10.

Simpson E, Silverberg J, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister K . Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021; 22(5):693-707. PMC: 8370859. DOI: 10.1007/s40257-021-00618-3. View

11.

Papp K, Szepietowski J, Kircik L, Toth D, Eichenfield L, Leung D . Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021; 85(4):863-872. DOI: 10.1016/j.jaad.2021.04.085. View

12.

Brewer M, Yoshida T, Kuo F, Fridy S, Beck L, Benedetto A . Antagonistic Effects of IL-4 on IL-17A-Mediated Enhancement of Epidermal Tight Junction Function. Int J Mol Sci. 2019; 20(17). PMC: 6747459. DOI: 10.3390/ijms20174070. View

13.

Marie R, Abuzeid A, Attia F, Anani M, Gomaa A, Atef L . Serum level of interleukin-22 in patients with cutaneous warts: A case-control study. J Cosmet Dermatol. 2020; 20(6):1782-1787. DOI: 10.1111/jocd.13779. View

14.

Dickson M, Hahn W, Ino Y, Ronfard V, Wu J, Weinberg R . Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol. 2000; 20(4):1436-47. PMC: 85304. DOI: 10.1128/MCB.20.4.1436-1447.2000. View

15.

Annunziato F, Romagnani C, Romagnani S . The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2014; 135(3):626-35. DOI: 10.1016/j.jaci.2014.11.001. View

16.

Solimani F, Meier K, Ghoreschi K . Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol. 2019; 10:2847. PMC: 6901833. DOI: 10.3389/fimmu.2019.02847. View

17.

Etienne L, Joshi P, Dingle L, Huang E, Grzesik P, Desai P . Visualization of herpes simplex virus type 1 virions using fluorescent colors. J Virol Methods. 2016; 241:46-51. PMC: 5661875. DOI: 10.1016/j.jviromet.2016.12.012. View

18.

Nogueira M, Puig L, Torres T . JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs. 2020; 80(4):341-352. DOI: 10.1007/s40265-020-01261-8. View

19.

COPEMAN P, Wallace H . ECZEMA VACCINATUM. Br Med J. 1964; 2(5414):906-8. PMC: 1816899. DOI: 10.1136/bmj.2.5414.906. View

20.

Strittmatter G, Sand J, Sauter M, Seyffert M, Steigerwald R, Fraefel C . IFN-γ Primes Keratinocytes for HSV-1-Induced Inflammasome Activation. J Invest Dermatol. 2016; 136(3):610-620. DOI: 10.1016/j.jid.2015.12.022. View